Drug Profile

Atebimetinib - Immuneering

Alternative Names: IMM-1-104

Latest Information Update: 19 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Immuneering
Class Antineoplastics; Small molecules
Mechanism of Action Mitogen-activated protein kinase kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pancreatic cancer
New Molecular Entity Yes

Highest Development Phases

Phase I/II Solid tumours

Most Recent Events

07 Jan 2026 Efficacy data from a phase I/IIa trial in Pancreatic cancer released by Immuneering
17 Dec 2025 Immuneering completes end of phase 2 meeting with US FDA
13 Nov 2025 Immuneering plans clinical trial for non-small cell lung cancer(Combination therapy, Late-stage disease, First-line therapy) in 2H 2026 (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com